{"id":989676,"date":"2026-08-04T19:31:46","date_gmt":"2026-08-04T23:31:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-highlights\/"},"modified":"2026-08-04T19:31:46","modified_gmt":"2026-08-04T23:31:46","slug":"tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-highlights\/","title":{"rendered":"Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n – Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) –<\/i>\n <\/p>\n

\n – Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th<\/sup> dose level, now expected end of Q1 2027 –<\/i>\n <\/p>\n

\n – Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy –<\/i>\n <\/p>\n

\n – Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway into 2H 2028 –<\/i>\n <\/p>\n

\n CARLSBAD, Calif.<\/span>, Aug. 4, 2026<\/span> \/PRNewswire\/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June\u00a030, 2026, and highlighted recent corporate progress.<\/p>\n

“September marks an important milestone for TYRA as we prepare to share initial clinical data from SURF302 evaluating oral dabogratinib in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Patients with IR NMIBC often endure a lifelong cycle of recurrent disease, repeated surgical procedures, catheterization, and ongoing surveillance, highlighting the need for more convenient and effective treatment options. We believe dabogratinib has the potential to redefine the treatment paradigm as the first targeted oral therapy for FGFR3-driven IR NMIBC, addressing the underlying biology of the disease while offering the convenience of an oral therapy,” said Todd Harris, PhD, President and Chief Executive Officer of TYRA.<\/p>\n

Dr. Harris continued, “Beyond SURF302, we continue to advance our broader pipeline, including progressing BEACH301 to a fifth dose level in achondroplasia, and strengthening our skeletal dysplasia leadership with the addition of Jonathan Day, whose work was instrumental in the development of vosoritide. Across our portfolio, we remain focused on realizing the full potential of oral dabogratinib for patients with FGFR3-driven conditions and diseases.”<\/p>\n

“Over the past decade, I’ve had the privilege of helping advance therapies that have transformed the treatment landscape for children with achondroplasia. I believe there is still meaningful opportunity to further improve outcomes, and TYRA’s highly selective approach to FGFR3 inhibition offers a compelling opportunity to do just that,” commented Dr. Day, TYRA’s newly appointed Executive Vice President, Clinical Development.\u00a0“I’m excited to join the team and help advance dabogratinib as we work to develop a differentiated oral therapy for children with achondroplasia and their families.”<\/p>\n

\n Second Quarter and Recent Corporate Highlights<\/b>\n <\/p>\n

\n Dabogratinib 3×3 Strategy<\/b>\n <\/p>\n

In the second quarter of 2026, TYRA continued to advance its “dabogratinib 3×3” strategy: developing the first orally available, FGFR3-selective inhibitor in 3 future potentially pivotal clinical studies to support regulatory submissions with the aim to commercialize in 3 potential blockbuster indications: LG-UTUC, IR NMIBC and ACH.<\/p>\n